scholarly journals Evolution of HER2-low expression from primary to recurrent breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Federica Miglietta ◽  
Gaia Griguolo ◽  
Michele Bottosso ◽  
Tommaso Giarratano ◽  
Marcello Lo Mele ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Tumor ◽  
Triple Negative ◽  
Recurrent Breast Cancer ◽  
Her2 Expression ◽  
Disease Evolution ◽  
Drug Conjugates ◽  
Negative Tumor ◽  
Recurrent Breast ◽  
Low Expression

AbstractAbout a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. HER2 was evaluated according to ASCO/CAP recommendations in place at the time of diagnosis. A cutoff of >10% cells staining for HER2-positivity was applied. HER2-negative cases were sub-classified as HER2-low (IHC = 1 + /2+ and ISH not amplified), or HER2-0 (IHC-0). 547 patients were included. The proportion of HER2-low cases was 34.2% on the primary tumor and 37.3% on the relapse samples. Among HER2-negative cases, HER2-low status was more frequent in HR-positive vs triple-negative tumors (47.3% vs 35.4% on primary tumor samples, 53.8% vs 36.2% on relapse samples). The overall rate of HER2 discordance was 38.0%, mostly represented by HER2-0 switching to HER2-low (15%) and HER2-low switching to HER2-0 (14%). Among patients with a primary HER2-negative tumor, the rate of HER2 discordance was higher in HR-positive/HER2-negative vs triple-negative cases (45.5% vs 36.7% p = 0.170). This difference was mostly driven by cases switching from HER2-0 to HER2-low. HER2-low expression is highly unstable during disease evolution. Relapse biopsy in case of a primary HER2-0 tumor may open new therapeutic opportunities in a relevant proportion of patients.

scholarly journals Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Francesco Schettini ◽  
Nuria Chic ◽  
Fara Brasó-Maristany ◽  
Laia Paré ◽  
Tomás Pascual ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Overall Survival ◽  
High Activity ◽  
Triple Negative ◽  
Her2 Expression ◽  
Drug Conjugates ◽  
Molecular Features ◽  
Biological Heterogeneity ◽  
Antibody Drug

AbstractNovel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.

Elevated neutrophil to lymphocyte ratio to predict survival outcome after recurrence for patients with triple-negative breast cancer.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 24-24
Author(s):  
Toshiaki Iwase ◽  
Takafumi Sangai ◽  
Masahiro Sakakibara ◽  
Takeshi Nagashima ◽  
Masaru Miyazaki
Keyword(s):  
Breast Cancer ◽  
Chronic Inflammation ◽  
Triple Negative ◽  
Recurrent Breast Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
World Health ◽  
Skeletal Muscle Index ◽  
Lymphocyte Ratio ◽  
Recurrent Breast ◽  
The Impact

24 Background: Recent studies show that obesity plays a major role in causing chronic inflammation by producing several inflammatory cytokines. On the other hand, there is limited research focusing on the effect of obesity in recurrent breast cancer treatments. Therefore, we set out to clarify the impact of obesity related inflammation by Neutrophil to Lymphocyte ratio (N/L ratio) in recurrent breast cancer treatment. Methods: From January 2005 to December 2014, 93 patients with recurrent breast cancer after surgery were included. World Health Organization body mass index (BMI) classification was used for evaluating the degree of obesity. Muscle mass amount was also analyzed. Lumber skeletal muscle index (LSMI, cm2/m2) was generated by standardizing each patient’s muscle area (m2) at the third lumber vertebrae level in axial CT data. Less than 50m2 in LSMI was defined as pre-sarcopenia. N/L ratio was calculated from the laboratory data, and more than 3.0 was defined as high N/L group. Results: Patient background showed there were 20 overweight patients and 2 obese patients. Twenty-eight cases had pre-sarcopenia. In univariate analysis, N/L ratio had no significant differences among BMI categories. However, triple negative (TN) type demonstrated significantly high N/L ratio compared to other subtypes (p < 0.05). LMSI had significant negative correlation to N/L ratio (p < 0.05). In survival analysis, Overweight/Obese group showed significantly shorter OS (p < 0.05). High N/L ratio group also showed similar results (p < 0.05). When stratified by intrinsic subtypes, TN type demonstrated significantly shorter OS (p < 0.05). Additionally, Overweight/Obese groups in TN type had notably shorter OS (p < 0.05). In multivariate analysis, subtype and N/L ratio were independently related to OS (Hazard ratio: 3.3 in TN type, 2.9 in High NL ratio group). Conclusions: Present study did not show any significant relationship between obesity and chronic inflammation in recurrent breast cancer setting. On the contrary, intrinsic subtype was significantly related to inflammation, leading to pre-sarcopenia and worse OS. Whether obesity promotes inflammation in TN type needs more investigation.

Comparative study of hormone receptor status and HER2 expression between primary and recurrent breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e21050-e21050
Author(s):  
N. Rokutanda ◽  
J. Horiguchi ◽  
D. Takata ◽  
R. Nagaoka ◽  
A. Sato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Comparative Study ◽  
Hormone Receptor ◽  
Recurrent Breast Cancer ◽  
Hormone Receptor Status ◽  
Her2 Expression ◽  
Receptor Status ◽  
Recurrent Breast

Mammographic findings of recurrent breast cancer after lumpectomy and radiation therapy: comparison with the primary tumor.

Radiology ◽  
1996 ◽  
Vol 201 (3) ◽  
pp. 767-771 ◽  
Author(s):  
L E Philpotts ◽  
C H Lee ◽  
B G Haffty ◽  
R C Lange ◽  
I Tocino
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Primary Tumor ◽  
Recurrent Breast Cancer ◽  
Recurrent Breast

scholarly journals Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Thi Hoa Nguyen ◽  
Van Hung Nguyen ◽  
Thanh Long Nguyen ◽  
Cai Qiuyin ◽  
Thi Huyen Phung
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Recurrent Breast Cancer ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Tissue Samples ◽  
Conversion Rates ◽  
Recurrent Breast

Background. Obtaining tumor specimens and re-evaluating targeted markers is recommended, if possible, in breast cancer patients who relapsed after curative treatment. The biomarker status changes in rebiopsied tumors have been demonstrated to have considerable clinical implications. Objectives. To identify the changes of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status between the primary and recurrent lesions. Materials and Methods. We conducted a study among 67 patients with recurrent breast cancer, recruited from January 2014 to September 2018 in the Vietnam National Cancer Hospital to compare ER, PR, and HER2 status between the primary and recurrent lesions. For each patient, a specimen of their primary tumor and another specimen of recurrent lesions underwent pathological assessment. Immunohistochemistry (IHC) was performed to determine ER, PR, and HER2 status in both specimens. Results. Biomarker status conversion rates (in both directions) between primary and recurrent tumors were 26.9% for ER, 38.8% for PR, and 22.4% for HER2. Overall, IHC subtypes (hormone receptor positive, HER2 amplified, and triple-negative) changed in 25 out of 67 (37.3%) cases. Conversion rates were not statistically significantly different between patients with different recurrent sites and times of recurrence. Eight out of 13 initially triple-negative patients (61.5%) had a change to positive status of either ER, PR, or HER2. Conclusion. A substantial discordance in ER, PR, and HER2 status were observed between primary breast cancer tissues and recurrent lesions. Rebiopsy could bring new therapeutic opportunities in the management of patients with recurrent breast cancer.

Sign in / Sign up

Export Citation Format

Share Document